FDA Approves New Oral Option for Plaque Psoriasis - Quiz - MDSpire

FDA Approves New Oral Option for Plaque Psoriasis

Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.

  • By

  • Kathryn Wighton

  • March 18, 2026

  • 2 min

Share

Original Source(s)

FDA Approves New Oral Option for Plaque Psoriasis

  • by Kathryn Wighton

  • March 18, 2026

Related Content

Semaglutide Use Linked to Erythromelalgia Remission

Case details diagnostic workup and rapid symptom resolution following GLP-1 receptor agonist initiation.

From Sophie Spitz to Molecular Melanocytoma

How one woman's pioneering research transformed pediatric melanoma diagnosis

Therapies for Infantile Haemangiomas: Current Practice and Evolving Perspectives